Biopharma hiring is broken in a way that looks strategic on paper.
Most teams build IP portfolios like theyre standalone assetsthen wonder why the organization cant translate those assets into faster decisions, cleaner diligence, or smarter partnering….
The generic cliff doesnt hit anymoreits engineered around.
For years, the story of drug patents was simple: a blockbuster wins, exclusivity ends, generics arrive, revenue falls off a cliff. But the modern playbook in pharma is less about waiting for …
Patent thickets are the new moatand biologics are where they get built.
If youve ever wondered why some blockbuster biologic therapies seem to never really go generic, the answer is often less about science and more about strategy. In a recent piece …
AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Most people think patent risk is something you handle after youve already committedafter the licensing deal, after the formulation work, after the market window opens. In pharma, th…
AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay Read Post »
Most teams look for new patents. The winners look for design-around space.
If youre building a pipeline, launching a product, or investing in generics/biosimilars, you already know the obvious part: patents can block timelines. But the real competitive…
Russias VED system has always been a quiet lever in global pharmauntil now. With Russias recent VED/SSM lists updates, the market signal is clear: generic entry timing is no longer just a question of regulatory readiness. Its a question of patent intel…
Russia’s VED & SSM Lists: How to Time Generic Entry Using Patent Expiration Data Read Post »
Pharma pipelines dont fail because of science. They fail because of risk you didnt see.
Thats the uncomfortable truth behind many surprise generic entries, licensing dead-ends, and launch delays. The root cause is often the same: teams move fast on R&a…
Freedom to Operate in Pharma: The Step-by-Step FTO Analysis That Protects Your Pipeline Read Post »
Beyond the ANDA: How the 505(b)(2) Pathway Can Turn Copy Into Competitive Moat
Most pharma conversations about generics start and end with the ANDA. Its familiar, its measurable, and its often the fastest route to market. But if youre trying to build s…
Pharma IP teams are used to thinking in patent years. But in Russia, the clock can movefastand the consequences are immediate.
Russias patent-term extension landscape is changing in ways that can make or break market exclusivity, pricing strategy, and …
Russia Patent-Term Extensions: What Every Pharma IP Team Needs to Know Right Now Read Post »
Your drug patent portfolio shouldnt just sit thereit should work.
In pharma, patents are often treated like static assets: file, publish, wait. But the market doesnt reward waiting. Competitors dont pause. Regulators dont slow down. And litigationwhe…
Get new actionable insights and updates from BiotechBlog
